This effect is likely caused by an increase in CD163 macrophage (M2-type macrophage) cells (Guillot et al., 2022), which have the potential to drive tumor progression by suppressing T cell-mediated anti-tumor immunity (Etzerodt et al., 2012; Cheng et al., 2017). This evidence concerns the gene CD163 and neoplasm.